The Fast MDx Platform
Fully automated safe testing with inactivate samples aspirated from the sealed Pathtubes® inside the Fast MDx platform.
The first fully automated Festo High-Throughput MDx liquid handling system, has been designed and optimized to work with the ultra-fast qPCR NGx2 thermal cycler.
Approved cyber security and fully integration into healthcare provider Laboratory Information Management Systems (LIMS).
Manufacturing under a BSi audited ISO13485 Quality Management System.
The Fast MDx platform has been designed to be manufactured initially with MHRA and CE-IVDr and subsequently with FDA regulatory approval.
Testing
Fast MDx will launch in late 2022 with a CE-IVDr approved high-throughput syndromic respiratory test for flu A, flu B, RSV A, RSV B and COVID-19.
Blood testing for prenatal detection of Rhesus D genotype and early cancer detection of free circulating tumour cells in blood will be available on the platform in 2023.
All tests will be MHRA and CE-IVDr approved when launched.